RMB Capital Management LLC lowered its holdings in Impax Laboratories (NASDAQ:IPXL) by 18.9% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 103,631 shares of the specialty pharmaceutical company’s stock after selling 24,099 shares during the period. RMB Capital Management LLC owned about 0.14% of Impax Laboratories worth $2,016,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Rhumbline Advisers raised its holdings in shares of Impax Laboratories by 14.0% during the fourth quarter. Rhumbline Advisers now owns 177,081 shares of the specialty pharmaceutical company’s stock valued at $2,948,000 after buying an additional 21,775 shares during the last quarter. California Public Employees Retirement System raised its holdings in shares of Impax Laboratories by 8.9% during the fourth quarter. California Public Employees Retirement System now owns 127,428 shares of the specialty pharmaceutical company’s stock valued at $2,122,000 after buying an additional 10,428 shares during the last quarter. First Trust Advisors LP bought a new stake in shares of Impax Laboratories during the fourth quarter valued at approximately $1,150,000. Element Capital Management LLC bought a new stake in shares of Impax Laboratories during the fourth quarter valued at approximately $2,463,000. Finally, TCW Group Inc. raised its holdings in shares of Impax Laboratories by 3,904.5% during the fourth quarter. TCW Group Inc. now owns 1,987,950 shares of the specialty pharmaceutical company’s stock valued at $33,099,000 after buying an additional 1,938,307 shares during the last quarter. 90.41% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:IPXL opened at $18.30 on Wednesday. Impax Laboratories has a 12 month low of $13.05 and a 12 month high of $25.70. The company has a market cap of $1.35 billion, a P/E ratio of 29.05, a PEG ratio of 0.83 and a beta of 1.15. The company has a current ratio of 1.96, a quick ratio of 1.52 and a debt-to-equity ratio of 4.11.

IPXL has been the topic of a number of recent analyst reports. BidaskClub cut Impax Laboratories from a “hold” rating to a “sell” rating in a report on Friday, February 16th. Zacks Investment Research raised Impax Laboratories from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a report on Friday, March 16th. ValuEngine cut Impax Laboratories from a “hold” rating to a “sell” rating in a report on Monday, April 2nd. BMO Capital Markets boosted their target price on Impax Laboratories from $18.00 to $20.00 and gave the stock a “market perform” rating in a report on Monday, April 16th. Finally, Canaccord Genuity set a $19.00 target price on Impax Laboratories and gave the stock a “hold” rating in a report on Thursday, March 1st. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $22.19.

Impax Laboratories Profile

Impax Laboratories, Inc, a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Impax Generics and Impax Specialty Pharma. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements.

Want to see what other hedge funds are holding IPXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Impax Laboratories (NASDAQ:IPXL).

Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.